| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2003.12.004 |
| P698 | PubMed publication ID | 12860940 |
| P50 | author | Markus Schwaiger | Q57016855 |
| Thomas M. Link | Q88088445 | ||
| P2093 | author name string | Burkhard Schmidt | |
| Christian Peschel | |||
| Wolfgang A Weber | |||
| Volker Petersen | |||
| Leishia Tyndale-Hines | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glucose | Q37525 |
| lung cancer | Q47912 | ||
| glycobiology | Q899224 | ||
| chemotherapy | Q974135 | ||
| positron emission tomography | Q208376 | ||
| P304 | page(s) | 2651-2657 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. | |
| P478 | volume | 21 |
| Q37253248 | (18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib |
| Q38410245 | (18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. |
| Q42786728 | 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours |
| Q37165297 | 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model |
| Q46072247 | 18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. |
| Q35006097 | 18F-FDG PET/CT imaging in oncology |
| Q36201687 | 18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy |
| Q46385098 | 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT. |
| Q38838770 | A Comparison of microCT and microPET for Evaluating Lymph Node Metastasis in a Rat Model |
| Q36021562 | A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment |
| Q37721526 | A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment. |
| Q37200476 | A comparison between radiolabeled fluorodeoxyglucose uptake and hyperpolarized (13)C-labeled pyruvate utilization as methods for detecting tumor response to treatment |
| Q37594914 | A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC. |
| Q91709752 | A phantom study to assess the reproducibility, robustness and accuracy of PET image segmentation methods against statistical fluctuations |
| Q56114080 | A theory of limited metabolic energy and premenstrual syndrome symptoms: Increased metabolic demands during the luteal phase divert metabolic resources from and impair self-control |
| Q36591925 | Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer |
| Q38052458 | Advances in oncologic imaging: update on 5 common cancers |
| Q36341240 | Advances in positron emission tomographic imaging of lung cancer |
| Q45954854 | Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. |
| Q40559241 | Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer |
| Q54985847 | Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. |
| Q41856102 | Average CT in PET studies of colorectal cancer patients with metastasis in the liver and esophageal cancer patients. |
| Q36480167 | Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy |
| Q57494932 | Calibration Software for Quantitative PET/CT Imaging Using Pocket Phantoms |
| Q35550041 | Cancer associated fibroblasts in hematological malignancies |
| Q37982927 | Cancer biomarkers: selecting the right drug for the right patient |
| Q46075809 | Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI. |
| Q34724752 | Comparison of texture features derived from static and respiratory-gated PET images in non-small cell lung cancer |
| Q36295403 | Computerized PET/CT image analysis in the evaluation of tumour response to therapy |
| Q46171346 | Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. |
| Q46581110 | Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer |
| Q44569104 | Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer |
| Q35445146 | Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer |
| Q38297892 | Developing biomarker-specific end points in lung cancer clinical trials |
| Q38396160 | Diagnostic evaluation for interventional bronchoscopists and radiologists in lung cancer practice. |
| Q46694112 | Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer |
| Q36012091 | Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells |
| Q36154024 | Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer? |
| Q39704817 | Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET. |
| Q47388017 | EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems |
| Q36014679 | Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study |
| Q46015577 | Early assessment of therapeutic response using FDG PET in small cell lung cancer. |
| Q33392707 | Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). |
| Q46150915 | Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer |
| Q59376816 | Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma |
| Q46555693 | Early restaging whole-body (18)F-FDG PET during induction chemotherapy predicts clinical outcome in patients with locoregionally advanced nasopharyngeal carcinoma |
| Q39245990 | Effects of ROI Placement on PET-Based Assessment of Tumor Response to Therapy |
| Q39650109 | Evaluating the extent of cell death in 3D high frequency ultrasound by registration with whole-mount tumor histopathology |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q30645097 | Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures. |
| Q37584750 | Evaluation of the biodistribution of 11C-methionine in children and young adults |
| Q34310486 | Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target |
| Q46785948 | F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy |
| Q61814958 | F-FDG and C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study |
| Q37348247 | F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma |
| Q52987662 | FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. |
| Q36239986 | FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy |
| Q34572647 | FDG-PET in colorectal cancer |
| Q51347358 | FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results. |
| Q36655475 | FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma |
| Q46473492 | False positive accumulation in 18F fluorodeoxyglucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer |
| Q52676354 | Feasibility of state of the art PET/CT systems performance harmonisation. |
| Q38673721 | Fluorine-18 fluorodeoxyglucose positron emission tomography in the management of solitary pulmonary nodule: a review |
| Q64083313 | Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events |
| Q35550676 | Functional imaging in lung cancer |
| Q39643573 | High-glycolytic cancers and their interplay with the body’s glucose demand and supply cycle |
| Q37715868 | Identification of Metabolic Biomarkers Using Serial 18F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer |
| Q38852701 | Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. |
| Q34256382 | Imaging in clinical trials. |
| Q38936273 | Imaging of Tumor Metabolism Using Positron Emission Tomography (PET). |
| Q44673116 | Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography. |
| Q34336023 | Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. |
| Q38260852 | Integrated FDG PET/CT: Utility and Applications in Clinical Oncology. |
| Q34768362 | Integrin alpha v beta 3-targeted imaging of lung cancer |
| Q53096881 | Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. |
| Q36194573 | Interpretation and Prognostic Value of Positron Emission Tomography-Computed Tomography After Induction Chemotherapy With or Without Radiation in IIIA-N2 Non-small Cell Lung Cancer Patients Who Receive Curative Surgery |
| Q55094487 | Is %ΔSUVmax a useful indicator of survival in patients with advanced nonsmall-cell lung cancer? |
| Q61448599 | Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome |
| Q49254379 | Low glucose metabolism in hepatocellular carcinoma with GPC3 expression |
| Q36824792 | Manipulations in HIWI level exerts influence on the proliferation of human non-small cell lung cancer cells |
| Q35667744 | Medical imaging in new drug clinical development |
| Q36024114 | Metabolic response assessment with (18)F-FDG PET/CT: inter-method comparison and prognostic significance for patients with non-small cell lung cancer |
| Q34243500 | Molecular imaging in therapeutic efficacy assessment of targeted therapy for nonsmall cell lung cancer |
| Q38838285 | Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers |
| Q36474962 | Monitoring chemotherapy and radiotherapy of solid tumors |
| Q37395352 | Morphologic and Metabolic Comparison of Treatment Responsiveness with 18Fludeoxyglucose-Positron Emission Tomography/Computed Tomography According to Lung Cancer Type |
| Q36567875 | Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size. |
| Q37059650 | New approaches for imaging tumour responses to treatment |
| Q36158583 | Noise considerations for PET quantification using maximum and peak standardized uptake value |
| Q37085729 | Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography |
| Q37465205 | PET imaging for Treatment Response in Cancer |
| Q84379472 | PET-CT in the staging and treatment of non-small-cell lung cancer |
| Q42961501 | PET/CT for diagnostics and therapy stratification of lung cancer |
| Q33665109 | PET/CT in Oncology: Current Status and Perspectives |
| Q38202189 | PET/CT in therapy evaluation of patients with lung cancer |
| Q44763677 | Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. |
| Q36221957 | Personalised medicine for cancer: from drug development into clinical practice |
| Q42941120 | Personalized versus evidence-based medicine with PET-based imaging |
| Q54292748 | Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. |
| Q46981176 | Positron emission tomography imaging in nonsmall-cell lung cancer |
| Q42056666 | Positron emission tomography in the management of lung cancer |
| Q35617157 | Positron emission tomography scanning for the diagnosis and management of lung cancer |
| Q36439506 | Positron emission tomography-computed tomography on predicting the efficacy of targeted therapy for lung adenocarcinoma |
| Q33657999 | Positron emission tomography/computerized tomography in lung cancer |
| Q35874704 | Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. |
| Q36815905 | Potential of 18F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer |
| Q35583933 | Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers |
| Q34810709 | Prediction of response by FDG PET early during concurrent chemoradiotherapy for locally advanced non-small cell lung cancer |
| Q51626116 | Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. |
| Q53404618 | Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma. |
| Q51333903 | Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. |
| Q36945656 | Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. |
| Q37129057 | Predictive and prognostic value of FDG-PET. |
| Q43605684 | Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib. |
| Q36628687 | Present role and future prospects of positron emission tomography in clinical oncology |
| Q37121347 | Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. |
| Q37681788 | Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas |
| Q36303765 | Promise and pitfalls of quantitative imaging in oncology clinical trials. |
| Q35761121 | Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. |
| Q35720347 | Pulmonary subsolid nodules: what radiologists need to know about the imaging features and management strategy |
| Q33727137 | Quantitative measurement of organic acids in tissues from gastric cancer patients indicates increased glucose metabolism in gastric cancer. |
| Q90094954 | Rapid regression of microsatellite instability-high/programmed cell death ligand 1-negative recurrent endometrial carcinoma by immune checkpoint blockade with pembrolizumab: A case report and literature review |
| Q46218241 | Respiration-averaged CT for attenuation correction in non-small-cell lung cancer |
| Q36341962 | Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer |
| Q35843677 | Role of FDG-PET in the diagnosis and management of lung cancer |
| Q53490063 | Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. |
| Q55515056 | Simultaneous Estimation of Bias and Resolution in PET Images With a Long-Lived "Pocket" Phantom System. |
| Q34203953 | Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications. |
| Q24629149 | Stable isotope-resolved metabolomics and applications for drug development |
| Q81166832 | Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer |
| Q48428876 | Standardised uptake values from PET/CT images: comparison with conventional attenuation-corrected PET. |
| Q38240147 | Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation |
| Q36528175 | Targeted molecular imaging in oncology: focus on radiation therapy |
| Q27001239 | The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and Staging |
| Q37612645 | The Value of Establishing the Quantitative Accuracy of PET/CT Imaging. |
| Q36598427 | The future in advanced prostate cancer: take your partners or is the last dance for me? |
| Q36908974 | The impact of functional imaging on radiation medicine |
| Q40027009 | The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry |
| Q39938308 | The influence of respiratory motion on the cumulative SUV-volume histogram and fractal analyses of intratumoral heterogeneity in PET/CT imaging |
| Q37785870 | The metabolic switch and its regulation in cancer cells. |
| Q46839970 | The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab |
| Q36836254 | The prognostic value of PET and PET/CT in cervical cancer |
| Q38715401 | The role of PET/CT as a prognosticator and outcome predictor in lung cancer |
| Q55221692 | The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer. |
| Q37210598 | The role of positron emission tomography in the management of non-small cell lung cancer. |
| Q47725129 | The role of radionuclide probes for monitoring anti-tumor drugs efficacy: A brief review. |
| Q27021838 | The use and misuse of positron emission tomography in lung cancer evaluation |
| Q45953810 | The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT. |
| Q46209994 | Time-course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow |
| Q55209667 | Time‐course of effects of external beam radiation on [18F]FDG uptake in healthy tissue and bone marrow. |
| Q33806271 | Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors |
| Q36488080 | Treatment with the MEK inhibitor U0126 induces decreased hyperpolarized pyruvate to lactate conversion in breast, but not prostate, cancer cells |
| Q91994260 | Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient |
| Q90650632 | Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung |
| Q34096601 | Use of new imaging techniques to predict tumour response to therapy |
| Q45366338 | Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy |
| Q36039936 | Using imaging biomarkers to accelerate drug development and clinical trials |
| Q42868066 | Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response |
| Q37162301 | Value-Based Care in Lung Cancer |
| Q37359696 | [18 F]FDG-PET imaging is an early non-invasive pharmacodynamic biomarker for a first-in-class dual MEK/Raf inhibitor, RO5126766 (CH5126766), in preclinical xenograft models |
| Q81448123 | [Usefulness of positron emission tomography-computed tomography in respiratory medicine] |
Search more.